<DOC>
	<DOCNO>NCT00918034</DOCNO>
	<brief_summary>This phase 2 study evaluate safety effectiveness light-activated talaporfin sodium patient LUTS due benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Study Light-Activated Talaporfin Sodium Patients With Lower Urinary Tract Symptoms ( LUTS ) Due Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>This phase 2 study evaluate safety effectiveness use light-activated talaporfin sodium patient LUTS due BPH candidate interventional therapy . The eligible patient undergo placement proprietary drug activator prostatic urethra . Following placement drug activator , patient receive talaporfin sodium 1 mg/kg intravenously slow push 3-5 minute . Fifteen minute injection light dose 100 Joules per centimeter ( J/cm ) deliver 20 mW/cm patient treatment duration 1 hour 23 minute . SAE report occur day treatment ( Day 0 ) end study ( month 12 ) , inclusive . Any SAE still ongoing end study follow assessed chronic , stable resolve .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>1 . Males , age 50 year old prior diagnosis BPH ; 2 . Patients may eligible whether medication LUTS due BPH . 3 . Patients candidate interventional therapy ; 4 . Patients understand ability sign write informed consent prior study procedure and/or discontinuation exclusionary medication ; 5 . Patients International Prostate Symptom Score ≥ 15 point ; 6 . Patients moderate severe BPH ( Bother Score ≥ 3 ) ; 7 . Maximum urinary flow rate ( Qmax ) ≤ 15 mL/sec ; 8 . Post void residual volume ( PVR ) ≤ 300 mL ; 9 . Length prostatic urethra ≥ 4.0 cm . 1 . Patients previous minimally invasive surgical intervention BPH . 2 . Patients currently enrol enrol another clinical trial disease within past 30 day . 3 . Patients active urinary tract infection . 4 . Patients urethral stricture . 5 . Patients interstitial cystitis . 6 . Patients predominant middle lobe obstruction . 7 . Patients evidence history prostate bladder cancer carcinoma situ bladder . 8 . Patients abnormal digital rectal exam suggestive carcinoma prostate . 9 . Patients abnormal digital rectal exam suggestive indurated nodule . 10 . Patients PSA &gt; 10 ng/ml . If PSA 410 ng/ml , local standard care pursue ensure possibility prostate cancer follow ruled prior , entry study . 11 . Patients biopsy prostate within past 6 week . 12 . Patients bleed diathesis . 13 . Patients clinically significant renal hepatic impairment . 14 . Patients neurological condition felt affect bladder history neurogenic chronically decompensated bladder . 15 . Patients daily use pad device incontinence . 16 . Patients episode unstable angina pectoris , myocardial infarction , transient ischemic attack , cerebrovascular accident ( stroke ) within past 6 month , peripheral arterial disease intermittent claudication Leriches syndrome . 17 . Patient interest future fertility . 18 . Patients prolong QT interval baseline and/or currently take medication prolongs QT interval ( `` prolong QT interval '' define &gt; 450 m ) . 19 . Inadequate organ function evidence follow : Platelet count &lt; 100,000/mm3 ; WBC &lt; 4,000/mm3 ; Neutrophils &lt; 1,800/mm3 ; Hemoglobin &lt; 10 g/dL ; AST ALT &gt; 3 x ULN ; Creatinine &gt; 1.5 x ULN 20 . Known sensitivity porphyrintype drug know history porphyria . 21 . Inability avoid bright indoor light sunlight first 72 hour LS11 administration .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>BPH</keyword>
	<keyword>LUTS</keyword>
	<keyword>talaporfin sodium</keyword>
</DOC>